Home>Topics>Companies>Sanofi S.A.

Sanofi S.A.

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
  1. Health Care a Leader in Moat Stocks

    Video Reports

    Tue, 22 Jul 2014

    One of the names we like a lot right now is [TICKER: SNY ] Sanofi . This is a company that has a strong entrenchment in ..... advantage, another moat source for the firm. [TICKER: SNY ] Sanofi we think is very well-positioned for growth over the

    SNY Sanofi found at 2:45

    moats? Conover: One of the names we like a lot right now is [TICKER: SNY ] Sanofi . This is a company that has a strong entrenchment in multiple industries, but really led by its entrenchment in insulin. Insulin still has very strong pricing power partly due to patent protection, but also due to the complexity of manufacturing insulin, which also gives the firm a little bit of a cost advantage, another moat source for the firm. [TICKER: SNY ] Sanofi we think is very well-positioned for growth over the long term and a lot of it is attributable to its wide economic
  2. What Makes a Moat?

    Headlines

    Mon, 21 Jul 2014

    pharmaceutical companies, Sanofi SNY benefits from patent protection ..... cost of capital. Also, Sanofi 's unique entrenched position ..... cost insulin production. Sanofi 's existing product line ..... biologic markets exposes Sanofi to less-pronounced generic

  3. Positive Phase 2 results for dupilumab

    Headlines

    Wed, 9 Jul 2014

    Regeneron ( REGN +0.1% ) and development partner Sanofi ( SNY +0.8% ) report encouraging Phase 2b results for their investigational mAb dupilumab as a treatment for adults with moderate

  4. Sanofi Is Buying Shares Of Regeneron - You Should Too

    Headlines

    Wed, 9 Jul 2014

    combined. On July 1st, 2014, French drugmaker Sanofi ( SNY ) increased its stake in Regeneron ..... 5% in April and 16% in 2013. Sanofi has expressed interest and received ..... long-standing relationship with Sanofi , the fifth-largest pharmaceutical

  5. Sanofi sues Lilly over insulin patents

    Headlines

    Tue, 8 Jul 2014

    Abasria, a direct competitor to its top-selling Lantus , Sanofi ( SNY -0.7% ) files a patent infringement suit in the U ..... It will come off patent in February 2015. The filing of Sanofi 's original lawsuit triggered the automatic 30-month

  6. Sanofi sues Eli Lilly over insulin rival to Lantus

    Headlines

    Tue, 8 Jul 2014

    (Reuters) - Sanofi SA , whose top-selling Lantus helps diabetics control blood sugar levels, has filed a lawsuit accusing Eli Lilly and Co of infringing seven patents related to insulin and devices used to deliver it.

  7. Sanofi sues Eli Lilly over insulin rival to Lantus

    Headlines

    Tue, 8 Jul 2014

    July 8 (Reuters) - Sanofi SA , whose top-selling Lantus helps diabetics control blood sugar levels, has filed a lawsuit accusing Eli Lilly and Co of infringing seven patents related to insulin and...

  8. FDA accepts Toujeo NDA

    Headlines

    Tue, 8 Jul 2014

    The U.S. regulator accepts Sanofi 's ( SNY -0.3% ) NDA for its investigational basal insulin Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL). The

  9. Sanofi raises stake in Regeneron to 22.5 percent from 20.5 percent

    Headlines

    Tue, 1 Jul 2014

    July 1 (Reuters) - French drugmaker Sanofi SA will raise its stake in Regeneron Pharmaceuticals Inc to 22.5 percent, Sanofi said in a U.S. regulatory filing Tuesday, as part of an agreement between...

  10. UPDATE 1- Sanofi -led group buys Globalpharma stake from Dubai Investments

    Headlines

    Thu, 26 Jun 2014

    DUBAI, June 26 (Reuters) - French drugmaker Sanofi is leading an investor group buying a 66 percent stake in the Globalpharma unit of Dubai Investments, the Gulf-based diversified investment group said on Thursday.

« Prev12345Next »
Content Partners